




GP1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	FODSTAD ET AL.	Examiner:	M. DAVIS
Serial No.:	09/331,376	Group Art Unit:	1642
Filed:	JUNE 18, 1999	Docket:	788565USWO12
Due Date:	JANUARY 6, 2000		AM 9:40
Title:	METHOD FOR CHARACTERIZATION OF ABNORMAL CELLS		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on January 6, 2000.

By: 
John J. Gresens

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

We are transmitting herewith the attached:


- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Response to Restriction Requirement
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
3100 Norwest Center, Minneapolis, MN 55402
(612) 332-5300

By: 
Name: John J. Gresens
Reg. No.: 33,112
JJG:PSTslc

S/N 09/331,376



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	FODSTAD ET AL.	Examiner:	M. DAVIS
Serial No.:	09/331,376	Group Art Unit:	1642
Filed:	JUNE 18, 1999	Docket No.:	7885.65USWO
Title:	METHOD FOR CHARACTERIZATION OF ABNORMAL CELLS		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on January 5, 2000.

By: 
Name: John J. Gresens

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This paper is being submitted in response to the Restriction Requirement mailed December 7, 1999.

In the Claims

Please cancel claims 5 and 12.

Please amend claims 1, 6, 7, and 13 as indicated below.

1. (Amended) Method to detect and phenotype target cells, such as animal and human cells, in cell suspensions by using particles coated with antibodies[/ligands] directed against antigenic determinants/receptors expressed on the target cells, except when the target cells are malignant and normal haemotopoietic and lymphatic cells,

characterized in that 2-6 antibodies [or ligands], each antibody [or ligand] conjugated to each of several types of particles instrumentally or visually separable by fluorescence, color and size, with sizes ranging from 0.01 μm - 6 μm , wherein the ratio between the number of particles and the number of cells ranges from 20:1 to 0.5:1, are incubated under gentle rotation

BI
Case